Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Kura Oncology (KURA)

Kura Oncology (KURA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Kura Oncology and Kyowa Kirin Present Promising Phase 1a Data for Ziftomenib in Treating NPM1-m and KMT2A-r Acute Myeloid Leukemia at ASH Annual Meeting Quiver Quantitative, Inc. - Mon Dec 9, 4:18PM CST

Komet-007 shows high complete remission rates for AML with ziftomenib, demonstrating promising safety and efficacy in ongoing studies.Quiver AI SummaryKura Oncology and Kyowa Kirin announced promising...

KURA : 9.01 (+0.45%)
Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting GlobeNewswire - Mon Dec 9, 6:00AM CST

KURA : 9.01 (+0.45%)
Kura Oncology to Host Virtual Investor Event on KOMET-007 Trial of Ziftomenib Following ASH Annual Meeting Quiver Quantitative, Inc. - Mon Dec 2, 4:48PM CST

Kura Oncology will host a virtual investor event on December 9 to discuss ziftomenib's clinical trial updates.Quiver AI SummaryKura Oncology, Inc. announced a virtual investor event set for December 9,...

KURA : 9.01 (+0.45%)
Kura Oncology to Host Virtual Investor Event on December 9, 2024 GlobeNewswire - Mon Dec 2, 6:30AM CST

KURA : 9.01 (+0.45%)
Kura Oncology, Inc. to Participate in JMP Securities Hematology and Oncology Summit with CEO Troy Wilson Scheduled for Virtual Fireside Chat Quiver Quantitative, Inc. - Mon Nov 25, 4:48PM CST

Kura Oncology will participate in a virtual fireside chat at the JMP Securities Summit on December 2, 2024.Quiver AI SummaryKura Oncology, Inc., a clinical-stage biopharmaceutical company specializing...

KURA : 9.01 (+0.45%)
Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit GlobeNewswire - Mon Nov 25, 6:30AM CST

KURA : 9.01 (+0.45%)
Kura Oncology Stock Slips Following Collaboration With Kyowa: Retail Turns Extremely Bullish Stocktwits - Thu Nov 21, 12:02PM CST

Retail sentiment on the stock rose to ‘extremely bullish’ (92/100) from ‘neutral’ (52/100) a week ago. Message volumes rose to ‘extremely high’ levels.

KURA : 9.01 (+0.45%)
VTI : 293.28 (+1.14%)
IWM : 221.92 (+0.94%)
Kura Oncology and Kyowa Kirin Announce Strategic Collaboration for Ziftomenib Development with $330 Million Upfront Payment Quiver Quantitative, Inc. - Thu Nov 21, 2:24AM CST

Kura and Kyowa Kirin collaborate to develop ziftomenib for AML, providing substantial milestone payments and joint commercialization efforts.Quiver AI SummaryKura Oncology and Kyowa Kirin have announced...

KURA : 9.01 (+0.45%)
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias Newswire.ca - Wed Nov 20, 4:00PM CST

– Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including $420 million in near-term milestone payments and...

KURA : 9.01 (+0.45%)
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias GlobeNewswire - Wed Nov 20, 4:00PM CST

KURA : 9.01 (+0.45%)

Barchart Exclusives

Scalp a 47% Payout by the End of This Week with Micron (MU) Call Spreads Barchart - Sat Dec 21, 9:15AM CST
Yes, there are serious questions about MU stock following the underlying company’s disappointing earnings but a steady march is all options traders need. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot